FBLG - FibroBiologics, Inc. News

Discover

FBLG

FibroBiologics, Inc.

0.91

7 x 1.00

1 x 1.01

bid

ask

-

0.04

4.37%

4 @ 04:00 PM

0.93 +0.03 (2.99%)

Ytd	-79.86%
1y	-92.46%

0.90

day range

0.98

0.73

52 week range

14.68

Open	0.94	Prev Close	0.95	Low	0.90	High	0.98	Mkt Cap	4.72M
Vol	105.86K	Avg Vol	271.58K	EPS	-7.02	P/E	N/A	Forward P/E	-5.83
Beta	N/A	Short Ratio	13.56	Inst. Own	15.83%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	08-14	50-d Avg	1.09	200-d Avg	5.09	1yr Est	12.75

FBLG News

FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Co

HOUSTON, June 30, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a cli

FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under

$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds up

FibroBiologics Commences Up To $9M Offering Of Common Shares, Warrants

FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics" or the "Company"), a clinical-

FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rule

$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds up

FibroBiologics Receives U.S. Patent And Trademark Office Notice Of Allowance For Patented Applicatio

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology compa

FibroBiologics Doses First Participant In Its Phase 1/2 Clinical Study Of CYWC628 To Treat Diabetic

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology compa

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial

EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial

FibroBiologics Inc. (NASDAQ: FBLG) reports enrolling first patients in its Phase 1/2 trial for CYWC6